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Background: West Nile Virus (WNV) is an emerging mosquito-transmitted flavivirus that continues to spread and
cause disease throughout several parts of the world, including Europe and the Americas. Specific diagnosis of WNV
infections using current serological testing is complicated by the high degree of cross-reactivity between antibodies
against other clinically relevant flaviviruses, including dengue, tick-borne encephalitis (TBEV), Japanese encephalitis
(JEV), and yellow fever (YFV) viruses. Cross-reactivity is particularly problematic in areas where different flaviviruses
co-circulate or in populations that have been immunized with vaccines against TBEV, JEV, or YFV. The majority of
cross-reactive antibodies against the immunodominant flavivirus envelope (E) protein target a conserved epitope in
the fusion loop at the distal end of domain II.
Methods: We tested a loss-of-function bacterially expressed recombinant WNV E protein containing mutations in
the fusion loop and an adjacent loop domain as a possible diagnostic reagent. By comparing the binding of sera
from humans infected with WNV or other flaviviruses to the wild type and the mutant E proteins, we analyzed the
potential of this technology to specifically detect WNV antibodies.
Results: Using this system, we could reliably determine WNV infections. Antibodies from WNV-infected individuals
bound equally well to the wild type and the mutant protein. In contrast, sera from persons infected with other
flaviviruses showed significantly decreased binding to the mutant protein. By calculating the mean differences
between antibody signals detected using the wild type and the mutant proteins, a value could be assigned for
each of the flaviviruses, which distinguished their pattern of reactivity.
Conclusions: Recombinant mutant E proteins can be used to discriminate infections with WNV from those with
other flaviviruses. The data have important implications for the development of improved, specific serological assays
for the detection of WNV antibodies in regions where other flaviviruses co-circulate or in populations that are
immunized with other flavivirus vaccines.
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The mosquito-transmitted West Nile Virus (WNV) be-
longs to the Flaviviridae family of positive stranded RNA
viruses, which also includes other arthropod-borne viruses
such as dengue (DENV), tick borne encephalitis (TBEV),
Japanese encephalitis (JEV), and yellow fever (YFV) vi-
ruses. WNV circulates in nature between mosquitoes and
birds, but humans and other mammals also can be in-
fected. In humans, about twenty percent of infected indi-
viduals develop flu-like symptoms, whereas in a subset of
patients, primarily the elderly and immunocompromised,
severe and sometimes fatal neurological complications
can develop [1]. WNV was first isolated in Africa and later
found to circulate in Asia, Australia, and sporadically in
Europe. WNV was introduced into the United States in
1999 and rapidly spread throughout the Americas in the
ensuing decade [2]. In addition, WNV has become en-
demic in several Southern and Eastern European coun-
tries during the past five years [3-6].
Several genetic lineages of WNV exist, and most isolates
belong either to lineage 1 or lineage 2. Whereas in the
Americas only WNV strains belonging to lineage 1 have
been identified, in Europe strains of lineages 1 and 2 are
circulating, sometimes even in the same area [7,8].
WNV infections can be diagnosed by directly detecting
the viral RNA, or by measuring antibodies produced
against it in serum or cerebrospinal fluid (CSF). As viremia
is transient, of low magnitude, and often precedes clinical
manifestations, RNA detection can be challenging. In
comparison, IgM antibodies are produced approximately
4 to 7 days after infection and IgG antibodies appear a
few days later [9]. Therefore, antibody-based detection
systems, such as ELISAs or indirect immunofluorescence
tests, are commonly used for WNV diagnosis. However, a
limitation of serological diagnosis for WNV infection is
the structural similarity of the immunodominant envelope
(E) protein among Flavivirus genus members. Antibodies
produced against the E protein can be cross-reactive, lea-
ding to false-positive test results [10-12]. This problemFigure 1 Sequence alignment of fusion loop domain of E proteins from
WNV-Equad: WNV E-quadruple mutant (point mutations are marked in
acids positions of the full length protein are indicated in the top row.occurs in many parts of the world due to co-circulation of
different flaviviruses and historical vaccination with live
attenuated or inactivated TBEV, JEV, or YFV vaccines. In
Europe, cross-reactivity of antibodies against TBEV and
WNV has been observed, especially in countries where
TBEV vaccination is common [13]. Consequently, positive
results obtained with the existing methods must be con-
firmed by lower-throughput virus neutralization tests,
which require high-security and biosafety laboratories,
which adds to the expense of the testing and delay in
establishing a diagnosis [14].
Previous work has established that cross-reactive anti-
bodies target the highly conserved fusion loop of the
flavivirus E protein [15]. Moreover, binding of such cross-
reactive antibodies can be diminished by inserting muta-
tions into this epitope in the E protein or in virus-like par-
ticles (VLPs) [16-20]. Here, using bacterially expressed
wild type or loss-of-function mutant WNV E proteins, we
evaluated the binding of antisera derived from humans in-
fected with different flaviviruses. This assay allowed us to
determine rapidly and reliably WNV infections.
Methods
Antigens
The WNV E ectodomain (amino acid residues 1 to 404)
and the quadruple mutant (T76A, M77G, W101R, L107R)
of the New York 1999 strain (Acc. Nr. FJ151394) were
expressed from the pET21a plasmid in Escherichia coli,
and purified after an oxidative refolding protocol, as de-
scribed previously [20,21]. The proteins were isolated as a
monodispersed peak on a Superdex 75 or 200, 16/60 size-
exclusion column using fast-protein liquid chromato-
graphy (GE Healthcare).
Serum samples
Serum samples from confirmed WNV-infections (described
in [22]) were obtained during outbreaks in Italy and Greece
in 2010. The Italian samples (University of Padova, Italy)
were derived from seroprevalence studies, blood donorsdifferent flaviviruses, WNV E: West Nile virus wild type E-protein,
red), TBEV-E: TBEV, DENV: DENV E protein, serotypes 1–4. Amino
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approval was obtained from the Padova University Hos-
pital ethics committee. The Greek samples (University of
Thessaloniki, Greece) were obtained from patients with
neuroinvasive disease, taken during the acute phase of
illness (3–17 days). WNV infections were confirmed
by virus neutralization tests. Ethical approval was ob-
tained from the Medical School of Aristotle University
of Thessaloniki ethics committee. Two WNV-positive
samples were obtained from Seracare Life Sciences (USA).
Serum samples from Canada were obtained from patients
with confirmed WNV-specific T-cell responses [21]. The
study was approved by the Hamilton Health Sciences/
McMaster Health Sciences research ethics board. None of
the patients was vaccinated against other flaviviruses or
had a recent travel history to other countries endemic for
WNV. Serum samples from JEV-vaccinated individuals
participating in a randomized controlled vaccination study
(approved by the national ethics committee) were ob-
tained from the Robert-Koch Institute (Berlin, Germany).
Sera from confirmed TBEV and DENV-infected indi-
viduals and negative controls were obtained from Padova
University Hospital (Italy). All confirmed DENV cases
were international travellers returning from endemic
countries with diagnosis of recent primary DENV infec-
tion and with laboratory tests positive for IgM/IgG or IgG
against only DENV. Confirmed TBEV IgG-positive serum
samples were selected from a seroprevalence study in
forest rangers. The TBEV IgG-positive samples were fromFigure 2 Analyses of WNV infected human sera on 50 ng per well of
the mutant Equad (black columns), sera from different areas, as indicsubjects vaccinated against TBEV or with a history of con-
firmed TBEV infection. The neutralizing titer for WNV
was negative in all of these cases (data not shown). Ethical
approval was obtained from the Padova University Hos-
pital ethics committee.
All persons participating in this research provided
informed consent and all samples were analyzed
anonymously.
Antibodies against DENV were detected by using
DENV IgG and IgM capture DxSelect (Focus Diagnos-
tics, Cypress, CA, USA). Antibodies against TBEV were
tested by using anti-TBE Virus IgG, IgM Enzygnost®
ELISA (Siemens Healthcare, Germany).
Antibody measurements
Nunc polysorb plates (Thermo Scientific, Germany) were
coated overnight with indicated amounts of recombinant
E ectodomain protein or E-quadruple mutant (in coating
buffer (15 mM Na2CO3, 35 mM NaHCO3 pH 9.6)) per
well with gentle agitation at 4°C. The plates were washed
three times with 350 μL per well of PBS/Tween (0.05%),
followed by blocking with 5% non-fat dry milk powder
(200 μL per well) for 2 h at room temperature (RT). After
a second wash step, human sera (dilution 1:100 in 5%
non-fat dry milk powder, 100 μL per well) were incubated
for 1.5 h at RT. The sera were removed by a third wash
step and 100 μL of the secondary antibody (1:10.000
diluted HRP-conjugated Goat-anti-Human IgG (Fisher
Scientific)) was added for 1 h at RT. After washing, thethe microtiter plate of E wild type (grey columns) compared to
ated next to the numbers (G: Greece, I: Italy, C: Canada, US: USA).
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wells and the plate was incubated for 30 min at RT in
darkness. To stop the reaction, 1 M H2SO4 was added,
followed by measurement at 450 nm and 520 nm (refe-
rence wavelength) in an ELISA Reader (Infiniti M200,
Tecan). All antibody tests were performed in duplicates in
at least two independent experiments.
Equal loading of wild type and mutant E protein was
verified using the humanized E16 monoclonal antibody
(dilution 1:1000), which targets an epitope on domain III
of the E protein, distant from the fusion loop [23] (data
not shown).
Statistical analysis
Statistical analysis was performed using Mann–Whitney
Rank Sum Test in SigmaStat.
Results and discussion
To analyze the influence of the E protein fusion loop on
the specificity of flavivirus IgG antibody binding to theFigure 3 Comparison of IgG binding to 50 ng per well of wild type E
TBEV- or DENV- positive sera. Asterisks indicate statistically significant dif
**, P = <0.001; DENV: *, P = 0.010; Mann–Whitney Rank Sum Test).E protein, we used a bacterially expressed wild type
E-protein and a loss-of-function mutant (Equad), which
contains four mutations within and proximal to the fusion
loop [20] (Figure 1). Both proteins were incubated with
sera from humans infected with WNV from outbreaks
in Europe and America. Although the overall signal
strength varied substantially between individuals, all sam-
ples showed clearly detectable signals that did not differ
markedly between the wild type and the mutant E-
proteins (Figure 2). Binding was similar in sera from pa-
tients infected with WNV strains belonging to genetic
lineage 1 or lineage 2 [24], as demonstrated by signals ob-
tained with sera from the United States, Canada or Italy
(lineage 1) and Greece (lineage 2). Next, the assay was
evaluated for its specificity by testing sera from humans
containing antibodies against the heterologous flaviviruses,
TBEV and DENV. In contrast to the WNV-positive sam-
ples, we observed statistically significant differences in
binding between the wild-type and quadruple mutant E
proteins (Figure 3). Most samples showed the expected(grey columns) and Equad (black columns) using negative (NEG),
ferences between wild type and mutant WNV-Envelope protein (TBEV:
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WNV E; however, the values for binding of the hetero-
logous sera to the fusion loop mutant were substantially
lower. Although some DENV-infected sera showed bind-
ing to the mutant WNV E protein, the values obtained
with the wild type E protein were all significantly higher.
To assess the relative amount of antibody against wild
type and mutant E proteins, sera from WNV-, TBEV- or
DENV-infected individuals were incubated with increasing
amounts of the two protein antigens in the solid phase.Figure 4 Antigen titration of Equad (A) and E wild type (B). Different s
proteins per well of the microtiter plate. Differences between individual serFor the WNV-positive sera, the signal for binding the
Equad mutant saturated at ~200 ng per well (Figure 4). In
contrast, saturation was not observed with the wild type
protein until 300 ng of protein was added. This possibly
reflects the limiting amount of WNV-specific antibodies
that target other non-fusion loop epitopes. Increasing
the antigen amount from 50 ng to 100 ng resulted in
enhanced detection of sera, especially for those showing
moderate binding at the lower amounts, as exemplified
by WNV serum 7 (see Figure 2), but increased theera were incubated with an increasing amount of recombinant
a at 300 ng of antigen were not statistically significant.
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Serum dilution assays confirmed the marked differences
in titers against the mutant and the wild type E protein
shown by the DENV- and TBEV positive sera (Figure 5).
By calculating the average ratios between the signal for
the wild-type and mutant protein in Figures 1 and 2, a
value could be assigned for each of the flaviviruses, which
distinguished their pattern of reactivity. For WNV, the
average ratio was 1.22 (standard deviation (SD) of 0.2), for
DENV 5.92 (SD of 3.1) and for TBEV 6.06 (SD of 2.1),
with a statistically significant difference between WNVFigure 5 Sera dilution curves using constant antigen amounts (100 nand the other two infections (P = 0.005, Mann–Whitney
Rank Sum Test).
To analyze the suitability of this system to discriminate
between infections with different flaviviruses of the JEV-
serocomplex, we analyzed sera from individuals vacci-
nated against JEV. Due to the low antibody titres in these
sera 100 ng of antigen per well were required. Similar to
the DENV and TBEV infections, in all samples there was
decreased binding to the Equad antigen compared to the
wild-type E protein (Figure 6). However, under the condi-
tions used, the differences were less pronounced and notg) of the Equad mutant (A) and wild type E protein (B).
Figure 6 Comparison of IgG binding to wild type E (grey columns) and Equad (black columns) using negative (NEG), WNV-, TBEV-,
DENV- and JEV-positive sera.
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ples, a finding which is not unexpected given the higher
amino acid sequence identity (approx. 80%) of the WNV
E-protein to JEV as compared to TBEV or DENV (approx.
40% and 50%, respectively). This indicates that the prin-
ciple of discrimination also applies to JEV, but the defi-
nition of average ratios will require more refinement for
WNV-related viruses from the same JEV serocomplex.
In summary, we present a new assay for the serologic
diagnosis of WNV infections, which is based on the rela-
tive difference in antibody binding to mutant and wild type
E protein of WNV. The data suggest that defined values
could be established that allow the differentiation of flavi-
virus infections. The observation that antibody binding to
the E protein varied substantially among WNV-infected
individuals is consistent with previous observations de-
scribing the heterogeneity of the human humoral immune
response to WNV infections [22,25]. However, for WNV,
there were no significant differences observed between the
binding towards wild type and mutant E protein, unless
the antigens were present at high density. Because the
human antibody response against WNV is skewed to-
wards non-neutralizing epitopes including the fusion
loop [21,26], some difference in binding was expected.
However, DENV- and TBEV- positive sera show a more
pronounced difference in the binding to wild type and
mutant E protein, which reflects the immunodominance
of the fusion-loop epitope as a cross-reactive determinant
[18,27-29]. Although diminished binding of cross-reactive
DENV-infected sera using a similar Equad protein has
been shown previously [20], sera from WNV- and TBEVinfected patients were not analyzed in that study. The
quadruple mutant contains four mutations adjacent to
and within the fusion loop of the protein, which impact
the binding of cross-reactive flavivirus antibodies. Using a
VLP-based system, Roberson et al. [19] analyzed a double-
mutant (G106R and L107H) in the fusion loop of the
E protein for WNV diagnosis. Our approach differs in
number and positions of the mutations and in the antigen
platform. A recombinant bacteria-derived protein has the
advantage over mammalian cell-culture derived VLPs as it
can be produced rapidly, inexpensively, and in higher
yield, and likely can be quantified more precisely for diag-
nostic applications. Therefore, our results may be useful
for the development of a specific rapid diagnostic test for
the detection of WNV IgG and possibly, IgM antibodies.
IgM detection would be particularly useful for the investi-
gation of recent infections. Alternatively, a recent infec-
tion can also be diagnosed by measuring a rise in IgG
antibody titers over time [11].Conclusions
By using a recombinant loss-of-function mutant of the
WNV E-protein, infections with WNV can be discrimi-
nated from those with TBEV and DENV based on anti-
body measurements. Whereas under the conditions used
no substantive difference in binding of WNV antibodies
to the wild type or mutant E protein was observed, anti-
TBEV or –DENV antibodies bound significantly less well
to the mutant protein lacking the cross-reactive fusion
loop epitope.
Chabierski et al. BMC Infectious Diseases 2014, 14:246 Page 8 of 8
http://www.biomedcentral.com/1471-2334/14/246Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
SC and JMR carried out the immunoassays and produced the recombinant
antigens. SU, SC and MSD conceived and designed the experiments and
wrote the paper. LB, MN, AP, JLB and GP contributed reagents/materials/
analysis tools and added important intellectual input into study design and
writing of the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
We thank Steffen Jakob for excellent technical assistance. This work was
supported by the European Commission under FP7, project number 261426
(WINGS; Epidemiology, Diagnosis and Prevention of West Nile Virus in
Europe).
Author details
1Department of Immunology, Fraunhofer Institute for Cell Therapy and
Immunology, Perlickstrasse 1, 04103 Leipzig, Germany. 2Department of
Molecular Medicine, University of Padova, via Gabelli 63, 35121 Padova, Italy.
3Department of Microbiology, Medical School, Aristotle University of
Thessaloniki, 54124 Thessaloniki, Greece. 4Robert Koch Institute, 13353 Berlin,
Germany. 5McMaster Immunology Research Centre, McMaster University,
Hamilton, Ontario L8N 3Z5, Canada. 6Departments of Medicine, Molecular
Microbiology, Pathology & Immunology, Washington University School of
Medicine, 63110 St Louis, MO, USA.
Received: 17 December 2013 Accepted: 6 May 2014
Published: 9 May 2014
References
1. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL: Virology,
pathology, and clinical manifestations of West Nile virus disease. Emerg
Infect Dis 2005, 11:1174–1179.
2. Murray KO, Mertens E, Despres P: West Nile virus and its emergence in the
United States of America. Vet Res 2010, 4:67.
3. Barzon L, Pacenti M, Franchin E, Lavezzo E, Martello T, Squarzon L, Toppo S,
Fiorin F, Marchiori G, Russo F, Cattai M, Cusinato R, Palu G: New endemic
West Nile virus lineage 1a in northern Italy, July 2012. Euro Surveill 2012,
17:e2023117.
4. Sirbu A, Ceianu CS, Panculescu-Gatej RI, Vazquez A, Tenorio A, Rebreanu R,
Niedrig M, Nicolescu G, Pistol A: Outbreak of West Nile virus infection in
humans, Romania, July to October 2010. Euro Surveill 2011, 16:e19762.
5. Sambri V, Capobianchi M, Charrel R, Fyodorova M, Gaibani P, Gould E,
Niedrig M, Papa A, Pierro A, Rossini G, Varani S, Vocale C, Landini MP:
West Nile virus in Europe: emergence, epidemiology, diagnosis,
treatment, and prevention. Clin Microbiol Infect 2013, 8:699–704.
6. Papa A: West Nile virus infections in Greece: an update. Expert Rev Anti
Infect Ther 2012, 10:743–750.
7. Magurano F, Remoli ME, Baggieri M, Fortuna C, Marchi A, Fiorentini C, Bucci
P, Benedetti E, Ciufolini MG, Rizzo C, Piga S, Salcuni P, Rezza G, Nicoletti L:
Circulation of West Nile virus lineage 1 and 2 during an outbreak in
Italy. Clin Microbiol Infect 2012, 18:E545–547.
8. Barzon L, Pacenti M, Franchin E, Squarzon L, Lavezzo E, Cattai M, Cusinato R,
Palù G: The complex epidemiological scenario of West Nile virus in Italy.
Int J Environ Res Public Health. 2013, 10:4669–4689.
9. Diamond MS, Mehlhop E, Oliphant T, Samuel MA: The host immunologic
response to West Nile encephalitis virus. Front Biosci 2009, 14:3024–3034.
10. Papa A, Karabaxoglou D, Kansouzidou A: Acute West Nile virus neuroinvasive
infections: cross-reactivity with dengue virus and tick-borne encephalitis
virus. J Med Virol 2011, 83:1861–1865.
11. Sambri V, Capobianchi MR, Cavrini F, Charrel R, Donoso-Mantke O, Escadafal C,
Franco L, Gaibani P, Gould EA, Niedrig M, Papa A, Pierro A, Rossini G, Sanchini
A, Tenorio A, Varani S, Vázquez A, Vocale C, Zeller H: Diagnosis of west nile
virus human infections: overview and proposal of diagnostic protocols
considering the results of external quality assessment studies. Viruses 2013,
5:2329–2348.
12. Sanchini A, Donoso-Mantke O, Papa A, Sambri V, Teichmann A, Niedrig M:
Second international diagnostic accuracy study for the serological
detection of West Nile virus infection. PLoS Negl Trop Dis 2013, 7:e2184.13. Donoso-Mantke O, Karan LS, Ruzek D: Tick-Borne Encephalitis Virus: A
General Overview. In Flavivirus Encephalitis. Edited by Ruzek D. Rijeka: InTech
Europe; 2011:133–156.
14. Maeda A, Maeda J: Review of diagnostic plaque reduction neutralization
tests for flavivirus infection. Vet J 2013, 1:33–40.
15. Crill WD, Chang GJ: Localization and characterization of flavivirus envelope
glycoprotein cross-reactive epitopes. J Virol. 2004, 78:13975–13986.
16. Diamond MS, Pierson TC, Fremont DH: The structural immunology of
antibody protection against West Nile virus. Immunol Rev 2008, 225:212–225.
17. Chiou SS, Crill WD, Chen LK, Chang GJ: Enzyme-linked immunosorbent
assays using novel Japanese encephalitis virus antigen improve the
accuracy of clinical diagnosis of flavivirus infections. Clin Vaccine Immunol
2008, 15:825–35.
18. Crill WD, Trainor NB, Chang GJ: A detailed mutagenesis study of flavivirus
cross-reactive epitopes using West Nile virus-like particles. J Gen Virol
2007, 88:1169–74.
19. Roberson JA, Crill WD, Chang GJ: Differentiation of West Nile and St. Louis
encephalitis virus infections by use of noninfectious virus-like particles
with reduced cross-reactivity. J Clin Microbiol 2007, 10:3167–74.
20. Vogt MR, Dowd KA, Engle M, Tesh RB, Johnson S, Pierson TC, Diamond MS:
Poorly neutralizing cross-reactive antibodies against the fusion loop of
West Nile virus envelope protein protect in vivo via Fcgamma receptor
and complementdependent effector mechanisms. J Virol 2011,
85:11567–11580.
21. Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, Loeb M, Throsby M,
Fremont DH, Pierson TC, Diamond MS: Induction of epitope-specific
neutralizing antibodies against West Nile virus. J Virol 2007,
81:11828–11839.
22. Chabierski S, Makert GR, Kerzhner A, Barzon L, Fiebig P, Liebert UG, Papa A,
Richner JM, Niedrig M, Diamond MS, Palù G, Ulbert S: Antibody responses
in humans infected with newly emerging strains of West Nile virus in
Europe. PlosOne 2013, 8:e66507.
23. Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, Fremont DH:
Structural basis of West Nile virus neutralization by a therapeutic
antibody. Nature 2005, 437:764–769.
24. Lanciotti RS, Ebel GD, Deubel V, Kerst AJ, Murri S, Meyer R, Bowen M,
McKinney N, Morrill WE, Crabtree MB, Kramer LD, Roehrig JT: Complete
genome sequences and phylogenetic analysis of West Nile virus strains
isolated from the United States, Europe, and the Middle East. Virology
2002, 298:96–105.
25. Faggioni G, Pomponi A, De Santis R, Masuelli L, Ciammaruconi A, Monaco F,
Di Gennaro A, Marzocchella L, Sambri V, Lelli R, Rezza G, Bei R, Lista F: West
Nile alternative open reading frame (N-NS4B/WARF4) is produced in
infected West Nile Virus (WNV) cells and induces humoral response in
WNV infected individuals. Virol J 2013, 22:283.
26. Throsby M, Geuijen C, Goudsmit J, Bakker AQ, Korimbocus J, Kramer RA,
Clijsters van der Horst M, de Jong M, Jongeneelen M, Thijsse S, Smit R,
Visser TJ, Bijl N, Marissen WE, Loeb M, Kelvin DJ, Preiser W, ter Meulen J, de
Kruif J: Isolation and characterization of human monoclonal antibodies
from individuals infected with West Nile Virus. J Virol 2006, 80:6982–6992.
27. Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X,
Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE Jr:
The potent and broadly neutralizing human dengue virus-specific mono-
clonal antibody 1C19 reveals a unique cross-reactive epitope on the bc
loop of domain II of the envelope protein. MBio 2013, 4:e00873–13.
28. Tsai WY, Lai CY, Wu YC, Lin HE, Edwards C, Jumnainsong A, Kliks S, Halstead
S, Mongkolsapaya J, Screaton GR, Wang WK: High-avidity and potently
neutralizing cross-reactive human monoclonal antibodies derived from
secondary dengue virus infection. J Virol 2013, 87:12562–12575.
29. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT,
Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L,
Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F: The human
immune response to Dengue virus is dominated by highly cross-reactive
antibodies endowed with neutralizing and enhancing activity. Cell Host
Microbe 2010, 8:271–283.
doi:10.1186/1471-2334-14-246
Cite this article as: Chabierski et al.: Distinguishing West Nile virus
infection using a recombinant envelope protein with mutations in the
conserved fusion-loop. BMC Infectious Diseases 2014 14:246.
